Amivantamab, as a first-line treatment of advanced EGFR-mutant NSCLC, has been developed in combination with lazertinib, an oral third-generation EGFR-TKI like osimertinib [19]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.